UPDATE: Pfizer’s U.S. sales of its COVID-19 vaccine, Comirnaty, have plummeted by 25% as the CDC narrows its recommendations on who should receive the shots. This drastic decline, reported for the third quarter of 2023, signals a troubling start to the fall vaccination season.
Sales dropped to $870 million in Q3 from $1.16 billion during the same period last year. The decline follows the federal government’s revised guidance, which now leaves vaccination decisions up to individuals rather than recommending annual boosters for all Americans aged 6 months and older. This shift is attributed to new advisories from officials, including Robert F. Kennedy Jr., who has questioned vaccine safety.
Experts warn that waning interest in COVID-19 vaccinations, combined with rising anti-vaccine sentiment, could further impact uptake this season. Dr. Amesh Adalja from the Johns Hopkins Center for Health Security noted that vaccination rates have been “suboptimal,” especially among those at high risk for severe COVID-19, and the current guidance could exacerbate this trend.
The CDC stopped recommending routine COVID-19 shots last month, which has led to confusion among the public and healthcare providers alike. As updated shots hit pharmacies, many locations began requiring prescriptions or questioning patients about their health conditions. This has led to uncertainty regarding insurance coverage, although the America’s Health Insurance Plans has clarified that coverage for the vaccines will continue.
CVS Health has eased some of this confusion by announcing it will not require prescriptions for vaccinations at its stores and clinics. However, independent pharmacies are experiencing mixed responses. Theresa Tolle, owner of Bay Street Pharmacy in Sebastian, Florida, reports an uptick in demand from older patients but also a noticeable hesitation among others. “There’s just so many messages out there; they don’t know who to believe,” she stated.
As Americans typically seek vaccinations in the fall to prepare for potential winter disease surges, the timing of this guidance shift could severely impact overall vaccination rates. With the updated shots arriving later than usual, many individuals remain uncertain about their necessity.
Wall Street analysts predict that Moderna’s Spikevax vaccine sales will also face a significant drop of approximately 50% in Q3, as reported by FactSet. Moderna is set to release its third-quarter results on Thursday, which will provide further insight into the national vaccination landscape.
As public health officials grapple with changing perceptions and guidance on COVID-19 vaccinations, the urgency for clear communication and effective outreach cannot be overstated. With the potential for vaccine rates to fall even further this season, the health implications for vulnerable populations could be profound.
Stay tuned for more updates as this situation develops.
